Citi initiated coverage of Regeneron (REGN) with a Neutral rating and $895 price target Multiple clinical data readouts should “keep ...

Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market The condition ...

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...

According to Parikh, diabetic retinopathy is the leading cause of blindness and severe vision loss among working-age people ...

SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...

Regeneron (REGN) Pharmaceuticals announced new and updated data from its hematology pipeline will be shared across 23 abstracts at the American Society of Hematology, ASH, 2024 Annual Meeting, taking ...

Professor Nancy Ip discusses her groundbreaking neuroscience research, focusing on neurotrophic factors and innovative ...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Over the summer, BioNTech released Phase 2 data on its mRNA cancer vaccine in the works alongside Regeneron. The vaccine, ...

THE DEPARTMENT of STEM Education in Mary Immaculate College (MIC) has collaborated with the University of Limerick (UL), and ...

The non-cystic fibrosis bronchiectasis market is driven by rising prevalence linked to respiratory infections, autoimmune diseases, and COPD. Increasing awareness among healthcare providers and ...